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In this issue of Neuron, Cruchaga et al. (2013) identify genetic variability linked to altered levels of tau protein
in cerebrospinal fluid. They show that the same genetic variants can also confer risk for Alzheimer’s disease.There is now a series of standard tools for
the generation and analysis of -ome-scale
human genotype data. Many scientific
questions have been asked using these
methods, but most have focused on the
traditional case-control genome-wide
association (GWA) study (Hardy and
Singleton, 2009). In the context of Alz-
heimer’s disease (AD) such approaches
have successfully identified a consider-
able number of loci that harbor risk
variants for disease (Harold et al., 2009;
Hollingworth et al., 2011; Lambert et al.,
2009; Naj et al., 2011; Seshadri et al.,
2010). A fairly standard approach to get-
ting more out of these data is to analyze
increasingly larger cohorts; increasing
n leads to greater power and a finer
resolution of the genetic basis of disease.
In this issue of Neuron, Cruchaga et al.
(2013) describe an alternate approach,
leveraging the power of genetics to find
variability that modulates a disease-rele-
vant endophenotype, and in turn using
these results to identify risk alleles for AD.
The notion of endophenotype as a route
to understanding the basis of disease
is one that has received considerable
attention in recent years, particularly in
the field of psychiatric genetics (Cruchaga
et al., 2012; Hinrichs et al., 2010; Kauwe
et al., 2007, 2008). The concept is simple
and centers on addressing a problem
that is particularly acute in late onset dis-
orders: the temporal distance between
initiation of a disease process and clinical
presentation is a long one. In this time,
myriad factors may alter the underlying
disease process, including those within
genetic, epigenetic, environmental, and
stochastic spheres; consequently, the ul-
timate outcome (i.e., disease presenta-
tion) can be highly variable. The endophe-
notype is meant to sit in the gap between
this alpha and omega, and in the best
case is a measure that directly—ratherthan indirectly—reflects the progression
of the underlying disease process.
Measuring an intermediate disease-
related event offers critical advantages
over readouts of clinical presentation;
such intermediate events can serve as
preclinical biomarkers of disease or as a
method to track progression. Because it
ismore proximal to the underlying disease
process, and probably a more objective
readout, intermediate events also may
have less innate variance.
In the current work, Cruchaga et al.
(2013) performed a GWA study on
1,300 cerebrospinal fluid (CSF) samples
measured for both tau and tau phosphor-
ylated at threonine 181 (ptau), both of
which are established biomarkers for
AD. As expected, Cruchaga et al. (2013)
showed that variability at APOE was
significantly associated with CSF levels
of both tau and ptau. Notably, however,
they also provide evidence that this asso-
ciation is in part independent of Ab42
levels in CSF, suggesting a route between
APOE alleles and tau levels that is not
mediated by Ab42. However, the central
finding of this article was the identification
of three novel genetic loci associated with
CSF ptau or tau levels, at 3q28, 9p24.2,
and 6p21.1. Interestingly, the latter
resides over the TREM gene cluster,
including TREM2, which was recently
shown to contain rare risk alleles for AD
(Guerreiro et al., 2013; Jonsson et al.,
2013). Investigating this locus further
showed that while the rare AD risk variant
at TREM2 (p.R47H) was indeed associ-
ated with CSF ptau and tau levels, there
were at least three independent alleles
associated with CSF tau/ptau at this
gene cluster. Besides APOE, none of the
tau/ptau-influencing loci identified here
were associated with CSF Ab levels.
Based on the notion that understanding
biomarkers for disease will ultimatelyNeurontell us more about the disease process,
Cruchaga et al. (2013) took the next
logical step and analyzed the identified
variants for association with AD, tau pa-
thology, and cognitive decline. They
show that variability at 3q28 associated
with CSF tau/ptau was also linked to risk
for AD, cognitive decline, and to levels of
neurofibrillary tangle pathology. Although
not quite as complete, the same type of
effect was previously noted at the TREM
gene cluster on 6p21.1, where TREM2
alleles had been associated with disease
(Guerreiro et al., 2013; Jonsson et al.,
2013). Lastly, Cruchaga et al. (2013) failed
to find evidence that the alleles linked to
CSF tau/ptau at 9p24.2 conferred risk
for AD, cognitive decline, or AD pathol-
ogy. There are many potential reasons
why this locus failed to associate with
disease. For instance, the tau/ptau asso-
ciation could simply be a type I error—
common in GWA, particularly in single-
stage designs with modest samples size.
More intriguingly, however, is the possibil-
ity that the effect allele at this locus alters
tau/ptau levels through a mechanism
unrelated to the disease process. While
Cruchaga et al. (2013) attempt to address
this by testing whether this locus is
broadly associated with protein clearance
from the CSF, this does not preclude a
more specific effect on tau/ptau clear-
ance. Such a finding may tell us little
about disease risk but may prove useful
in improving the information provided by
biomarkers. Identifying variants that alter
biomarkers for disease without altering
risk offers the opportunity to condition
biomarker levels based on nondisease-
related genetic variability and thus
improves the utility of these protein mea-
sures in predicting and tracking disease
(by removing/reducing biomarker vari-
ance unrelated to disease). While in isola-
tion the effect of the particular allele78, April 24, 2013 ª2013 Elsevier Inc. 207
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consequence on such an analysis, as
more alleles are identified, this may prove
to be a valuable approach.
Thus, of the four loci reported to influ-
ence CSF tau/ptau, three show robust ev-
idence for also altering risk for AD. In each
instance the direction of effect on CSF tau
and ptau, and on risk for AD, cognitive
decline, and tangle pathologywas consis-
tent; alleles associated with lower tau and
ptau were associated with reduced risk
for AD, slower cognitive decline, and
reduced neurofibrillary tangle pathology.
While this is an exciting piece of work
that supports the idea of using endophe-
notype to understand the basis of dis-
ease, there is still much to do. There exist
exciting opportunities and challenges in
taking the current findings further. GWA
studies identify loci, not genes, and as
such a critical next step is to identify the
pathobiologically relevant gene (or genes)
at the 3q28 locus and TREM gene cluster
and determine the effect of these risk al-
leles on that gene. For the most part, the
risk alleles associated by GWA are not
linked to protein-coding variability, and
in all likelihood they confer their effects
by altering transcript expression. While
Cruchaga et al. (2013) went some way to-
ward testing this—by examining the effect
of the identified alleles on expression of
proximal transcripts—this small explor-
atory study requires further work. Given
the recent identification of TREM2 as a
risk gene for AD, the identification of mul-
tiple independent alleles at this locus that
alter CSF tau/ptau is particularly exciting,
and further fine-scale investigation of this
locus is certainly warranted in AD.
Lastly, by Cruchaga et al. (2013)’s own
calculations, the four loci linked with208 Neuron 78, April 24, 2013 ª2013 ElsevierCSF tau/ptau levels only explain a minor
proportion of the variability in CSF tau/
ptau, indicating that at least some of the
remaining variability can be attributed to
as-yet-unknown genetic variants. Thus,
there are clearly more risk alleles to be
found. It is likely that the best route
to identify these unknown factors
will employ a combination of genetic
methods, including GWA and second-
generation sequencing. There is certainly
great promise in thesemethods; however,
analyzing cohorts of sufficient size will
be critical; approximately 1,300 CSF
samples are an impressive amount, but
making substantive future gains in this
area will probably require larger cohorts
and unified biological measures.
In summary, Cruchaga et al. (2013)
have taken an exciting step in showing
that the endophenotype is a valuable
and informative measure for understand-
ing disease. Their work has provided
valuable new insight into the basis of AD
and promises to be the impetus for ad-
dressing a new series of research ques-
tions in this field. Given their findings,
this effort certainly appears to be a
valuable addition to the massive con-
sortium-based case control analyses.REFERENCES
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